Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Almirall’s Loss of Aclidinium Could Be Glenmark’s Gain

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Hopes for oglemilast, Glenmark's chronic obstructive pulmonary disease candidate being developed by U.S.-based Forest Laboratories brightened after rival experimental drug aclidinium - also licensed by Forest - showed disappointing results in Phase III studies
Advertisement

Related Content

Glenmark Sets Up Clinical R&D Unit At Oxford As Drug Pipeline Swells
Glenmark Sets Up Clinical R&D Unit At Oxford As Drug Pipeline Swells
Glenmark’s Novel Molecule For Neuropathic Pain, Osteoarthritis To Enter Phase I Trials
Glenmark’s Novel Molecule For Neuropathic Pain, Osteoarthritis To Enter Phase I Trials
Advertisement
UsernamePublicRestriction

Register

SC069724

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel